ARPA-H has announced THRIVE, a up-to-$160 million, up to five-year program designed to accelerate bespoke in vivo gene editing therapies for rare diseases. The effort will back seven teams across different organ systems and technology approaches, with a requirement that teams start clinical trials by year three. The program is framed as a “moonshot” style funding mechanism meant to reduce time to first clinical testing while supporting trial design and deployment models. For biotech, the structure may influence how companies build scalable, regulator-ready gene-editing packages. The announcement signals federal momentum behind personalized gene editing, where manufacturing, delivery, and off-target characterization are often the primary bottlenecks.